Survivin反义寡核苷酸诱导K562/A02细胞凋亡的实验研究

来源 :中国癌症杂志 | 被引量 : 0次 | 上传用户:jwliangbo
下载到本地 , 更方便阅读
声明 : 本文档内容版权归属内容提供方 , 如果您对本文有版权争议 , 可与客服联系进行内容授权或下架
论文部分内容阅读
背景与目的:Survivin是最近发现的凋亡抑制基因,与白血病的发生和耐药有关,反义寡核苷酸可抑制survivin表达,诱导凋亡,增加药物的敏感性。本研究探讨survivin反义寡核苷酸对白血病耐药细胞K562/A02生长、凋亡和半胱氨蛋白水解酶3的活性的作用。方法:以脂质体转染survivin反义寡核苷酸,以MTT、RT-PCR、流式细胞术、荧光分光光度计分别检测survivin反义寡核苷酸对K562/A02细胞的生长抑制、survivin mRNA表达、凋亡和半胱氨蛋白水解酶3的活性。结果:survivin反义寡核苷酸对K562/A02细胞的生长抑制呈浓度-时间依赖性,与对照组相比,survivin mRNA表达降低36.2%(P<0.05),半胱氨蛋白水解酶3的活性增加67.6%(P<0.05);K562/A02细胞的凋亡率明显增加(14.48±2.65%vs 2.39±0.47%,P<0.005)。结论:survivin反义寡核苷酸通过抑制survivin表达,上调半胱氨蛋白水解酶3活性而诱导凋亡。 BACKGROUND & OBJECTIVE: Survivin is a newly discovered inhibitor of apoptosis, which is associated with the development of leukemia and drug resistance. Antisense oligonucleotides inhibit the expression of survivin, induce apoptosis and increase the sensitivity of the drug. This study was to investigate the effect of survivin antisense oligonucleotide on the growth, apoptosis and cysteine ​​protease 3 activity of K562 / A02 cells. Methods: Antisense oligonucleotides of survivin were transfected by liposome. The growth inhibition of K562 / A02 cells was detected by MTT, RT-PCR, flow cytometry and fluorescence spectrophotometer respectively. Survivin mRNA expression, apoptosis and cysteine ​​protease 3 activity. Results: The survivin antisense oligonucleotide inhibited the growth of K562 / A02 cells in a concentration - time dependent manner. Compared with the control group, survivin mRNA expression was decreased by 36.2% (P <0.05), while cysteine ​​protease 3 The activity of K562 / A02 cells increased by 67.6% (P <0.05). The apoptosis rate of K562 / A02 cells increased significantly (14.48 ± 2.65% vs 2.39 ± 0.47%, P <0.005). CONCLUSIONS: Survivin antisense oligonucleotide induces apoptosis by inhibiting survivin expression and up-regulating caspase-3 activity.
其他文献
背景与目的:对于亚洲和中国较为常见的PTCL,其生物学行为与B细胞NHL不同,往往表现为化疗疗效不佳,病情迁延,容易复发,预后不良。我们回顾性分析外周T细胞淋巴瘤-非特异性(PTC
手术是直肠癌治疗的主要手段。根治性手术后,局部复发的发生与原发肿瘤肠壁侵润的深度和淋巴结转移直接相关,也是直肠癌最常见的治疗失控部位。早期临床研究提示T1-2N0M0的局
背景与目的:小细胞肺癌(small cell lung cancer,SCLC)一线化疗疗效较好,然而一旦复发,治疗十分困难,目前尚未确定最佳二线化疗方案。因此,我们采用依立替康(irinotecan,CPT-11)联